This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?

barchart.com/story/news/36214924/this-leading-gene-editing-stock-could-be-going-private-should-you-buy-its-shares-first

The global cell therapy market was valued at $5.88 billion in 2024 and is on track to hit $44.39 billion by 2034, expanding at a striking 22.69% CAGR. Researchers credit this explosive growth to record investments in R&D and rapid-fire breakthroughs in biotechnology. In little more than…

This story appeared on barchart.com, 2025-11-19 20:42:21.
The Entire Business World on a Single Page. Free to Use →